Based on DREAMM-2 study results, belantamab-mafodotin received the approval as monotherapy at a dose of 2.5 mg/kg every 3 weeks in patients with R/R MM patients who have previously received four or more lines of therapy, including an anti-CD38 mAb, a PI, and an IMiD (7). The gene discussed is CD38; the disease is Miyoshi myopathy.